We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
QIAGEN is expanding test menus and automation, with new systems supporting second-half 2026 sales growth.
Partnerships are broadening QIAGEN's assay, automation and digital capabilities across key markets.
QGEN faces cautious customer spending and competition that may delay platform adoption.
QIAGEN N.V. (QGEN - Free Report) is well positioned for growth in the upcoming quarters, supported by continued test menu expansion. Meanwhile, strategic partnerships support assay development and create opportunities for recurring consumables revenues across clinical, research and biopharma markets. However, cautious customer spending, weaker research funding and intense competition may limit near-term growth and delay the adoption of new platforms.
In the past year, shares of this Zacks Rank #3 (Hold) company have lost 7.8% against the industry’s 21.3% growth. The S&P 500 composite has seen a 17.9% rise in the same time frame.
The leading provider of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA has a market capitalization of $9 billion. QIAGEN has earnings yield of 5.56% against the industry’s negative 15.63% yield.
Let’s delve deeper.
Tailwinds for QGEN Stock
Progress With Test Menu Expansion: QIAGEN continues to invest in menu breadth and workflow automation across core platforms. QIAstat-Dx expanded into bloodstream infection testing in Europe with two BCID panels covering 33 pathogens and 28 antimicrobial-resistance markers in about one hour. The Gastrointestinal panel also supported testing during the U.S. Cyclospora outbreak.
In sample preparation, QIAsymphony Connect was launched, while QIAsprint Connect began customer placements in second-quarter 2026. QIAmini remains on track for launch in fall 2026. Management expects new Sample Technologies systems and other product launches to contribute approximately two percentage points to the sequential improvement in second-half 2026 sales.
Strategic Collaborations to Drive Growth: QIAGEN uses strategic partnerships to expand assay development, automation and digital capabilities across its portfolio. In companion diagnostics, pharmaceutical collaborations support multi-year co-development programs and recurring consumables opportunities as associated therapies advance. The company is also working with DiaSorin and Inpeco on a fully automated QuantiFERON workflow targeted for the second half of 2027. In digital PCR, its collaboration with Hamilton is extending QIAcuity automation for cell and gene therapy applications.
QDI is also partnering with NVIDIA to combine curated biomedical knowledge with accelerated computing and AI tools for drug discovery. These collaborations broaden QIAGEN’s platform capabilities and support adoption across clinical, research and biopharma workflows.
Image Source: Zacks Investment Research
What Ails QGEN Stock?
Macro Risks and Demand Sensitivity: QIAGEN remains exposed to fluctuations in testing demand, research funding and customer capital spending across its global markets. In the second quarter of 2026, instrument sales declined at a low-teens CER rate as U.S. Life Sciences customers remained cautious.
NIH funding in the first half of 2026 remained below year-ago levels despite sequential improvement in the second quarter. PCR/Nucleic Acid Amplification sales fell 8% at CER, reflecting weaker OEM demand and lower sales of other PCR products. These trends indicate that research funding and capital spending remain important variables for near-term growth, particularly in Life Sciences markets.
Competitive Intensity: QIAGEN operates in highly competitive molecular testing, sample preparation and bioinformatics markets, where established workflows may make share gains and platform conversions more difficult. This is particularly relevant as the company introduces new automation systems, syndromic testing panels and digital PCR offerings that depend on customer adoption and subsequent consumables pull-through. Competitive alternatives can lengthen sales cycles and limit the pace at which new platforms gain scale. Over time, QIAGEN’s growth will depend on converting product launches into sustained placements and recurring consumables demand across its core markets.
QGEN Stock Estimate Trends
The Zacks Consensus Estimate for 2026 earnings per share (EPS) has remained unchanged at $2.43 in the past 30 days.
The Zacks Consensus Estimate for 2026 revenues is pegged at $2.14 billion, which indicates a modest 2.2% rise from the year-ago reported number.
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 28.2% against the industry’s 3.8% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, flaunting a Zacks Rank #1 at present, has an earnings yield of 6.7% against the industry’s negative 1.4% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 27.3% against the industry’s 3.8% decline over the past year.
Teleflex, currently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 14.5% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have gained 4% against the industry’s 3.7% decline over the past year.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now
Key Takeaways
QIAGEN N.V. (QGEN - Free Report) is well positioned for growth in the upcoming quarters, supported by continued test menu expansion. Meanwhile, strategic partnerships support assay development and create opportunities for recurring consumables revenues across clinical, research and biopharma markets. However, cautious customer spending, weaker research funding and intense competition may limit near-term growth and delay the adoption of new platforms.
In the past year, shares of this Zacks Rank #3 (Hold) company have lost 7.8% against the industry’s 21.3% growth. The S&P 500 composite has seen a 17.9% rise in the same time frame.
The leading provider of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA has a market capitalization of $9 billion. QIAGEN has earnings yield of 5.56% against the industry’s negative 15.63% yield.
Let’s delve deeper.
Tailwinds for QGEN Stock
Progress With Test Menu Expansion: QIAGEN continues to invest in menu breadth and workflow automation across core platforms. QIAstat-Dx expanded into bloodstream infection testing in Europe with two BCID panels covering 33 pathogens and 28 antimicrobial-resistance markers in about one hour. The Gastrointestinal panel also supported testing during the U.S. Cyclospora outbreak.
In sample preparation, QIAsymphony Connect was launched, while QIAsprint Connect began customer placements in second-quarter 2026. QIAmini remains on track for launch in fall 2026. Management expects new Sample Technologies systems and other product launches to contribute approximately two percentage points to the sequential improvement in second-half 2026 sales.
Strategic Collaborations to Drive Growth: QIAGEN uses strategic partnerships to expand assay development, automation and digital capabilities across its portfolio. In companion diagnostics, pharmaceutical collaborations support multi-year co-development programs and recurring consumables opportunities as associated therapies advance. The company is also working with DiaSorin and Inpeco on a fully automated QuantiFERON workflow targeted for the second half of 2027. In digital PCR, its collaboration with Hamilton is extending QIAcuity automation for cell and gene therapy applications.
QDI is also partnering with NVIDIA to combine curated biomedical knowledge with accelerated computing and AI tools for drug discovery. These collaborations broaden QIAGEN’s platform capabilities and support adoption across clinical, research and biopharma workflows.
Image Source: Zacks Investment Research
What Ails QGEN Stock?
Macro Risks and Demand Sensitivity: QIAGEN remains exposed to fluctuations in testing demand, research funding and customer capital spending across its global markets. In the second quarter of 2026, instrument sales declined at a low-teens CER rate as U.S. Life Sciences customers remained cautious.
NIH funding in the first half of 2026 remained below year-ago levels despite sequential improvement in the second quarter. PCR/Nucleic Acid Amplification sales fell 8% at CER, reflecting weaker OEM demand and lower sales of other PCR products. These trends indicate that research funding and capital spending remain important variables for near-term growth, particularly in Life Sciences markets.
Competitive Intensity: QIAGEN operates in highly competitive molecular testing, sample preparation and bioinformatics markets, where established workflows may make share gains and platform conversions more difficult. This is particularly relevant as the company introduces new automation systems, syndromic testing panels and digital PCR offerings that depend on customer adoption and subsequent consumables pull-through. Competitive alternatives can lengthen sales cycles and limit the pace at which new platforms gain scale. Over time, QIAGEN’s growth will depend on converting product launches into sustained placements and recurring consumables demand across its core markets.
QGEN Stock Estimate Trends
The Zacks Consensus Estimate for 2026 earnings per share (EPS) has remained unchanged at $2.43 in the past 30 days.
The Zacks Consensus Estimate for 2026 revenues is pegged at $2.14 billion, which indicates a modest 2.2% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and Teleflex (TFX - Free Report) .
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 28.2% against the industry’s 3.8% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Globus Medical, flaunting a Zacks Rank #1 at present, has an earnings yield of 6.7% against the industry’s negative 1.4% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 27.3% against the industry’s 3.8% decline over the past year.
Teleflex, currently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 14.5% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have gained 4% against the industry’s 3.7% decline over the past year.